Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 37.49M P/E - EPS this Y 37.00% Ern Qtrly Grth -
Income -31.96M Forward P/E -1.20 EPS next Y 12.70% 50D Avg Chg -36.00%
Sales - PEG - EPS past 5Y - 200D Avg Chg -33.00%
Dividend N/A Price/Book 1.87 EPS next 5Y - 52W High Chg -68.00%
Recommedations 2.20 Quick Ratio 2.15 Shares Outstanding 46.79M 52W Low Chg 24.00%
Insider Own 21.56% ROA -77.64% Shares Float 29.11M Beta 0.01
Inst Own 34.93% ROE -180.45% Shares Shorted/Prior 188.85K/278.20K Price 1.26
Gross Margin - Profit Margin - Avg. Volume 303,670 Target Price 8.25
Oper. Margin - Earnings Date - Volume 217,031 Change -3.82%
About IN8bio, Inc.

IN8bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of solid and liquid tumors. Its lead product candidates include INB-400, which is in Phase 2 clinical trial to treat newly diagnosed glioblastoma (GBM); INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of GBM and other cancers; and INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with hematologic malignancies undergoing hematopoietic stem cell transplantation. The company develops INB-300 and INB-500 that are in preclinical phase for treatment of acute myeloid leukemia, and other solid and hematological tumor types. The company was formerly known as Incysus Therapeutics, Inc. and changed its name to IN8bio, Inc. in August 2020. IN8bio, Inc. was incorporated in 2016 and is based in New York, New York.

IN8bio, Inc. News
12/10/24 IN8bio Reports Continued Progression-Free Survival in Phase 1 Investigator-Sponsored Trial of INB-100 Allogeneic Gamma-Delta T Cells for Leukemias at the 2024 American Society of Hematology Annual Meeting
12/02/24 IN8bio to Present at Noble Capital Markets' Twentieth Annual Emerging Growth Equity Conference
07:00 AM IN8bio Reports Continued Durable Remissions in Phase 1 Trial of INB-200 in Plenary Oral Presentation at the Society for Neuro-Oncology (SNO) Annual Meeting
11/14/24 INAB: Upcoming Presentations at SNO & ASH
11/12/24 IN8bio Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights
11/12/24 IN8bio Announces Plenary Oral Presentation at the 2024 Society for Neuro-Oncology (SNO) Annual Meeting
11/05/24 IN8bio Announces Upcoming Presentation at the 2024 American Society of Hematology (ASH) Annual Meeting
10/02/24 INAB: Restructuring Narrows Focus to AML
10/01/24 IN8bio Announces Pricing of $12.4 Million Private Placement
09/05/24 IN8bio cuts staff and pipeline to focus on AML cell therapy
09/04/24 IN8bio Announces Clinical Pipeline Prioritization to Focus on INB-100 for Acute Myeloid Leukemia
08/29/24 IN8bio to Present at the H.C. Wainwright 26th Annual Global Investment Conference
08/14/24 INAB: AML & GBM Clinical Update
08/12/24 IN8bio Solidifies Position as a Clinical Leader of Gamma-Delta T Cell Therapy in Oncology with 100% of Treated AML Patients in Complete Remission and Receives FDA Guidance for Registrational Trial of INB-100
08/08/24 IN8bio Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights
06/24/24 IN8bio to Present at the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference
06/17/24 INAB: INB-100 Update at EHA24 ¡Olé!
06/13/24 IN8bio Presents Positive Data Demonstrating Durable 1-year Complete Remission in 100% of Evaluable Patients in Phase 1 Trial of INB-100
06/05/24 INAB: INB-200 Update at ASCO24
06/03/24 IN8bio Presents Progression-Free Survival Update from Phase 1 Study of INB-200 at 2024 American Society of Clinical Oncology Annual Meeting
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Kreis Leslie W. Director Director Dec 12 Buy 2.48 75,001 186,002 570,724 12/13/22
Fletcher Aaron G.L. Director Director Dec 12 Buy 2.48 75,001 186,002 570,724 12/13/22
Fletcher Aaron G.L. Director Director Sep 28 Buy 2.02 25,000 50,500 561,989 09/29/22
Kreis Leslie W. Director Director Sep 28 Buy 2.02 25,000 50,500 561,989 09/29/22
Fletcher Aaron G.L. Director Director Aug 26 Buy 2.02 51,214 103,452 559,076 08/30/22
Kreis Leslie W. Director Director Aug 26 Buy 2.02 51,214 103,452 559,076 08/30/22
Kreis Leslie W. Director Director Aug 17 Buy 1.93 50,000 96,500 553,110 08/18/22
Fletcher Aaron G.L. Director Director Aug 17 Buy 1.93 50,000 96,500 553,110 08/18/22
Kreis Leslie W. Director Director Aug 16 Buy 1.9 1,773,684 3,370,000 540,287 08/17/22
Fletcher Aaron G.L. Director Director Aug 16 Buy 1.9 1,773,684 3,370,000 540,287 08/17/22